These findings suggested that TGF-β1 regulated EndMT in breast cancer via the TGF-β and Notch signaling pathways, and Snail and Slug may be key factors, implying that strategies which simultaneously inhibit TGF-β1, Snail and Slug may improve the effects of anti-angiogenic therapies in breast cancer. This evidence concerns the gene TGFB1 and breast carcinoma.